Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IG3018 in hyperuricemia with or without chronic kidney disease
NCT06310967Phase 2Recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Nov 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of IG3018 in hyperuricemia, sponsored by Intellia Therapeutics. Started Nov 2024; status: recruiting.
02
Drugs
IG3018
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT06310967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310967.